LAG3 and small cell lung carcinoma: Ieramilimab, an IgG4 mAb anti-LAG-3, has been evaluated in combination with spartalizumab (mAb anti-PD-1) in a phase II study enrolled patients with different tumor types including SCLC relapsed or refractory to standard therapies.